At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 56 enrolled
Drug / intervention
psilocybindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Psychopharmacology of Psilocybin in Cancer Patients
In Brief
A Phase 2 clinical trial evaluating psilocybin for Depressive Symptoms and 2 related conditions. Completed, enrolled 56 participants across 1 site.
Detailed Summary
This research is being done to study the psychological effects of psilocybin in cancer patients. Psilocybin is a naturally occurring substance found in some mushrooms that some cultures have used for centuries in religious practices.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Symptoms, Anxiety, Cancer
CountriesUnited States
CollaboratorsHeffter Research Institute
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2007
First PostedApr 2007
Primary CompletionDec 2014
Study CompletionDec 2016
TodayJul 2026
First PostedApr 25, 2007
Enrollment StartApr 1, 2007
Primary CompletionDec 1, 2014
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 19.2 years ago
Interventions
psilocybindrug
The dose of psilocybin received in the two sessions will range anywhere from low to high.